Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mrinalini Dey, Sizheng Steven Zhao & Robert J. Moots. (2021) Anti-TNF biosimilars in rheumatology: the end of an era?. Expert Opinion on Biological Therapy 21:1, pages 29-36.
Read now
Read now
Nizar Abdulateef Al Ani, Faiq I Gorial, Saad Al-Sulaitti, Jasmine Abbas Humadi, Nabaa Ihsan Awadh, Mohamed Mounir, Yasser El Dershaby, Heather Jones & Nancy Sunna. (2019) Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq. Open Access Rheumatology: Research and Reviews 11, pages 1-9.
Read now
Read now
Morton Scheinberg, Carlos Pineda, Gilberto Castañeda-Hernández, Juan José Zarbá, Aderson Damião, Luiz H Arantes Jr & Ira Jacobs. (2018) Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America. mAbs 10:6, pages 827-842.
Read now
Read now
Jihun Lee, Hyun Ah Kang, Jin Soo Bae, Kyu Dae Kim, Kyoung Hoon Lee, Ki Jung Lim, Min Joo Choo & Shin Jae Chang. (2018) Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. mAbs 10:4, pages 547-571.
Read now
Read now
Articles from other publishers (15)
Emmanuel Douez, Valentina D’Atri, Davy Guillarme, Daniel Antier, Mathieu Guerriaud, Alain Beck, Hervé Watier & Laura Foucault-Fruchard. (2023) Why is there no biosimilar of Erbitux®?. Journal of Pharmaceutical and Biomedical Analysis 234, pages 115544.
Crossref
Crossref
Neh Nupur, Srishti Joshi, Davy Gulliarme & Anurag S. Rathore. (2022) Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Crossref
Krzysztof Bonek, Leszek Roszkowski, Magdalena Massalska, Wlodzimierz Maslinski & Marzena Ciechomska. (2021) Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells 10:2, pages 323.
Crossref
Crossref
Bastiaan L. Duivelshof, Amarande Murisier, Julien Camperi, Szabolcs Fekete, Alain Beck, Davy Guillarme & Valentina D'Atri. (2020) Therapeutic Fc‐fusion proteins: Current analytical strategies. Journal of Separation Science 44:1, pages 35-62.
Crossref
Crossref
Lei Tian, Xiaomo Xiong, Qiang Guo, Yixi Chen, Luying Wang, Peng Dong & Aixia Ma. (2020) Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China. PharmacoEconomics 38:12, pages 1345-1358.
Crossref
Crossref
Ali M. Alsamil, Thijs J. Giezen, Toine C. Egberts, Hubert G. Leufkens, Arnold G. Vulto, Martijn R. van der Plas & Helga Gardarsdottir. (2020) Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. European Journal of Pharmaceutical Sciences 154, pages 105501.
Crossref
Crossref
Víctor Pérez Medina Martínez, Lilia Tierrablanca-Sánchez, Carlos E. Espinosa-de la Garza, Laura C. Juárez-Bayardo, Nelly Piña-Lara, Germán Gonzalez Santoyo & Néstor O. Pérez. (2020) Functional analysis of glycosylation in Etanercept: Effects over potency and stability. European Journal of Pharmaceutical Sciences 153, pages 105467.
Crossref
Crossref
Lun-Fei Liu, Ji-Su Chen, Jun Gu, Jin-Hua Xu, Hong-Zhong Jin, Xiao-Wen Pang, Gang Wang, Chen Yu, Zhi-Qiang Song, Zai-Pei Guo, Wei Li, Wei Lai, Pan-Gen Cui, Min Chen, Hong Fang, Cheng-Zhi Lyu, Yu-Zhen Li, Qing Sun, Hong-Fu Xie, Xiao-Ming Liu, Xing-Hua Gao, Yu-Ling Shi, Nai-Qing Zhao, Wei Zhang & Min Zheng. (2019) Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial. Archives of Dermatological Research 312:6, pages 437-445.
Crossref
Crossref
Nam Ah Kim, Bora Heo & Seong Hoon Jeong. (2019) Rapid methodology for basal system selection of therapeutic proteins during the early stage biopharmaceutical development. Journal of Pharmaceutical Investigation 50:4, pages 363-372.
Crossref
Crossref
Hans C. Ebbers, Bjørn Fehrmann, Mette Ottosen, Niels Hvorslev, Pia Høier, Jae-Woong Hwang, Jinhan Chung, Hyoung Taek Lim, Shinjung Lee, Juyoung Hong & Mourad Farouk Rezk. (2020) Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars. BioDrugs 34:2, pages 225-233.
Crossref
Crossref
Roy Fleischmann, Vipul Jairath, Eduardo Mysler, Dave Nicholls & Paul Declerck. (2020) Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. Rheumatology and Therapy 7:1, pages 35-64.
Crossref
Crossref
Alain Beck, Davy Guillarme, Sandrine Fleury-Souverain, Elsa Bodier-Montagutelli & Renaud Respaud. (2020) Anticorps monoclonaux biosimilaires. médecine/sciences 35:12, pages 1146-1152.
Crossref
Crossref
Hope S Rugo, Robert M Rifkin, Paul Declerck, Angel H Bair & Geraint Morgan. (2019) Demystifying biosimilars: development, regulation and clinical use. Future Oncology 15:7, pages 777-790.
Crossref
Crossref
Valderilio Feijó Azevedo, Alejandra Babini, Carlo V. Caballero-Uribe, Gilberto Castañeda-Hernández, Cecilia Borlenghi & Heather E. Jones. (2019) Practical Guidance on Biosimilars, With a Focus on Latin America. JCR: Journal of Clinical Rheumatology 25:2, pages 91-100.
Crossref
Crossref
Valentina D’Atri, Lucie Nováková, Szabolcs Fekete, Dwight Stoll, Matthew Lauber, Alain Beck & Davy Guillarme. (2018) Orthogonal Middle-up Approaches for Characterization of the Glycan Heterogeneity of Etanercept by Hydrophilic Interaction Chromatography Coupled to High-Resolution Mass Spectrometry. Analytical Chemistry 91:1, pages 873-880.
Crossref
Crossref